Trillium Therapeutics Inc. (T:TRIL)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Oct 28, 2021 05:00 pm ET

Trillium Therapeutics Receives Final Court Order Approving Arrangement

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the...

Oct 26, 2021 05:15 pm ET

Trillium Securityholders Approve Acquisition by Pfizer

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory...

Sep 03, 2021 05:15 pm ET

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

TORONTO, Sept. 3, 2021 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes to the S&P/TSX Composite Index prior to the open of trading on Monday, September 20, 2021:

Aug 23, 2021 06:45 am ET

Pfizer to Acquire Trillium Therapeutics Inc.

Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash. This represents a 118% premium to the 60-day weighted average price for Trillium.

Aug 23, 2021 06:45 am ET

Pfizer to Acquire Trillium Therapeutics Inc.

Aug 13, 2021 07:00 am ET

Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three and six months ended June 30, 2021....

Aug 09, 2021 07:00 am ET

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with...

Jul 06, 2021 07:00 am ET

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid leukemia (AML) patient with TTI-622...

Jun 30, 2021 07:00 am ET

Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader...

Jun 29, 2021 07:00 am ET

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

Jun 25, 2021 06:28 pm ET

Trillium Therapeutics Joins Russell 2000® and 3000® Indices

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russell 2000® and 3000® Indices effective...

Jun 09, 2021 07:00 am ET

Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual General and Special Meeting of...

May 07, 2021 07:00 am ET

Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

Apr 28, 2021 07:01 am ET

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc),...

Apr 28, 2021 07:00 am ET

Trillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance Changes

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a data update, announced Phase 1b/2 program priorities across seven hematologic and...

Apr 22, 2021 07:00 am ET

Trillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host its virtual R&D Day for analysts and investors at 10:00 a.m. –...

Mar 18, 2021 04:05 pm ET

Trillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D Day

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its CD47 clinical programs,...

Dec 07, 2020 04:05 pm ET

Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual...

Nov 25, 2020 07:00 am ET

Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology...

Nov 16, 2020 07:00 am ET

Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the nine months...

Nov 12, 2020 04:05 pm ET

Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader...

Nov 02, 2020 04:15 pm ET

Trillium Therapeutics Announces Formation of Scientific Advisory Board

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the formation of a Scientific Advisory Board (“SAB”),...

Nov 02, 2020 04:15 pm ET

Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of Ingmar Bruns, M.D., Ph.D. as Chief...

Oct 05, 2020 07:00 am ET

Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it has received Notices of Allowance from the...

Sep 18, 2020 07:00 am ET

Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader...

Sep 16, 2020 04:05 pm ET

Trillium Closes US$150 Million Public Offering of Common Shares

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten...

Sep 11, 2020 05:15 pm ET

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

TORONTO, Sept. 11, 2020 /CNW/ - As a result of the quarterly review, S&P Dow Jones Indices will make the following changes in the S&P/TSX Composite Index prior to the open of trading on Monday, September 21, 2020:

Sep 10, 2020 08:00 pm ET

Trillium Announces Pricing of US$130 Million Public Offering of Common Shares

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced...

Sep 09, 2020 04:01 pm ET

Trillium Announces Proposed Public Offering of Common Shares

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of up to...

Sep 08, 2020 04:56 pm ET

Trillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has agreed to sell 2,297,794 of its common...

Sep 08, 2020 04:05 pm ET

Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced updated data from its ongoing TTI-622 and TTI-621...

Aug 12, 2020 07:00 am ET

Trillium Therapeutics Reports Second Quarter 2020 Financial and Operating Results

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the six months...

Jul 30, 2020 07:00 am ET

Trillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG Level

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, provided an update today on its ongoing phase 1b dose optimization...

Jul 06, 2020 07:00 am ET

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

May 29, 2020 08:00 am ET

Trillium Therapeutics Provides Update on the Phase I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today data from an ongoing phase 1 dose escalation study of...

May 15, 2020 05:00 pm ET

Trillium Therapeutics Reports First Quarter 2020 Financial and Operating Results

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months...

May 13, 2020 07:00 am ET

Trillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific Program

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present data on its novel CD47 checkpoint inhibitor, TTI-622, at...

May 06, 2020 07:00 am ET

Trillium Therapeutics Announces “At-The-Market” Equity Program

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has established an at-the-market equity...

Apr 08, 2020 07:00 am ET

TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on the Company’s clinical trial activities...

Mar 20, 2020 10:40 am ET

IIROC Trade Resumption - TRIL

TORONTO, March 20, 2020 /CNW/ - Trading resumes in:

Mar 20, 2020 10:33 am ET

IIROC Trading Halt - TRIL

TORONTO, March 20, 2020 /CNW/ - The following issues have been halted by IIROC:

Mar 10, 2020 07:00 am ET

Trillium Therapeutics Reports Annual Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its transformation program,...

Feb 28, 2020 12:30 pm ET

Trillium Therapeutics Responds to Market Activity

At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL) wishes to confirm that it is not aware of any material, undisclosed information related to the Company...

Feb 28, 2020 11:49 am ET

IIROC Trade Resumption - TRIL

TORONTO, Feb. 28, 2020 /CNW/ - Trading resumes in:

Feb 28, 2020 11:39 am ET

IIROC Trading Halt - TRIL

TORONTO, Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:

Feb 28, 2020 10:58 am ET

IIROC Trade Resumption - TRIL

TORONTO, Feb. 28, 2020 /CNW/ - Trading resumes in:

Feb 28, 2020 10:55 am ET

IIROC Trading Halt - TRIL

TORONTO, Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:

Feb 28, 2020 09:06 am ET

IIROC Trade Resumption - TRIL

TORONTO, Feb. 28, 2020 /CNW/ - Trading resumes in:

Feb 28, 2020 09:01 am ET

IIROC Trading Halt - TRIL

TORONTO, Feb. 28, 2020 /CNW/ - The following issues have been halted by IIROC:

Feb 07, 2020 07:00 am ET

Trillium Therapeutics Announces Changes to Its Board of Directors

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s...

Jan 29, 2020 07:00 am ET

Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten...

Jan 23, 2020 08:15 am ET

Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced...

Jan 22, 2020 04:01 pm ET

Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common...

Jan 16, 2020 08:00 am ET

Trillium Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the Company has regained compliance with the...

Jan 07, 2020 08:30 am ET

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on its TTI-621 and TTI-622 clinical...

Nov 14, 2019 07:00 am ET

Trillium Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September...

Nov 06, 2019 07:00 am ET

Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that new preclinical data from its STING agonist program will be presented at the...

Oct 22, 2019 09:13 am ET

IIROC Trade Resumption - TRIL

TORONTO, Oct. 22, 2019 /CNW/ - Trading resumes in:

Oct 22, 2019 09:00 am ET

Trillium Therapeutics Announces Corporate Restructuring and Provides CD47 Program Update

Trillium Therapeutics Inc. (Trillium, "the company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced corporate restructuring to extend the company’s cash...

Oct 22, 2019 08:59 am ET

IIROC Trading Halt - TRIL

TORONTO, Oct. 22, 2019 /CNW/ - The following issues have been halted by IIROC:

Oct 08, 2019 07:00 am ET

Trillium Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule

Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC...

Sep 25, 2019 07:00 am ET

Trillium Therapeutics Appoints Jan Skvarka as President and Chief Executive Officer

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the appointment of Mr. Jan Skvarka as President and Chief Executive Officer effective...

Sep 05, 2019 07:00 am ET

Trillium Therapeutics To Present At Investor Conference

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present at the following upcoming investor...

Aug 13, 2019 07:00 am ET

Trillium Therapeutics Reports Second Quarter 2019 Financial Results

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the six months ended June 30, 2019. “We made excellent...

Jul 24, 2019 07:00 am ET

Trillium Therapeutics Provides Corporate Update

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update. “Trillium continues to make...

Jul 02, 2019 07:00 am ET

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 27,...

May 13, 2019 07:00 am ET

Trillium Therapeutics Reports First Quarter 2019 Financial Results

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the three months ended March 31, 2019. “We are continuing to...

Apr 30, 2019 07:00 am ET

Trillium Announces Management and Board Changes and Provides Corporate Update

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announces changes to its executive management team, its board of...

Apr 15, 2019 07:00 am ET

Trillium Therapeutics Announces Publication Highlighting Activity of TTI-621 in Sézary Syndrome Patients

Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the publication of data highlighting the role of TTI-621 in treating patients with...

Apr 11, 2019 07:00 am ET

Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 08, 2019 07:00 am ET

Trillium Therapeutics to Present at Investor Conferences in April

Apr 02, 2019 07:00 am ET

Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program

Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has expanded its immuno-oncology pipeline with a STING agonist program and...

Mar 27, 2019 05:00 pm ET

Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019

Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be presenting preclinical data from its previously undisclosed STING...

Mar 11, 2019 05:09 pm ET

Trillium Therapeutics Reports Annual Financial and Operating Results

Mar 08, 2019 06:37 pm ET

Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has closed its previously announced...

Feb 22, 2019 09:00 am ET

Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced...

Feb 22, 2019 08:43 am ET

IIROC Trade Resumption - TRIL

TORONTO, Feb. 22, 2019 /CNW/ - Trading resumes in:

Feb 22, 2019 08:10 am ET

IIROC Trading Halt - TRIL

TORONTO, Feb. 22, 2019 /CNW/ - The following issues have been halted by IIROC:

Feb 21, 2019 04:00 pm ET

Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of common...

Dec 03, 2018 07:00 am ET

Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that new clinical data from the ongoing intratumoral trial of its CD47-blocking...

Nov 14, 2018 07:00 am ET

Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results

Sep 28, 2018 07:00 am ET

Trillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific Conferences

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will be providing updates on its two clinical trials with TTI-621, a dual...

Sep 27, 2018 07:00 am ET

Trillium Therapeutics to Present at Upcoming Investor Conferences

Sep 12, 2018 07:00 am ET

Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings

Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company’s TTI-621...

Aug 30, 2018 09:30 am ET

Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it will be featured as a presenting company at the 20th Annual Rodman ...

Aug 08, 2018 07:00 am ET

Trillium Therapeutics Reports Second Quarter 2018 Financial and Operating Results

Jun 19, 2018 06:30 pm ET

Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) (“Trillium” or the “Company”), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into a sales agreement...

Jun 15, 2018 07:00 am ET

Trillium Therapeutics Completes Amendment to SIRPaFc License Agreement

Jun 14, 2018 07:00 am ET

Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47

Jun 07, 2018 07:00 am ET

Trillium Therapeutics Appoints Yaping Shou, MD, PhD as Chief Medical Officer

Jun 05, 2018 07:00 am ET

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June...

May 11, 2018 07:00 am ET

Trillium Therapeutics Reports First Quarter 2018 Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three months ended March 31, 2018....

Apr 18, 2018 07:00 am ET

Trillium Therapeutics Reports TTI-622 Preclinical Data at the 2018 AACR Annual Meeting

TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that preclinical data from its TTI-622 (SIRPa-IgG4 Fc) immune checkpoint inhibitor program...

Apr 12, 2018 07:00 am ET

Trillium Therapeutics to Report Preclinical Data on TTI-621 and TTI-622 at the AACR Annual Meeting 2018

TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced it will be presenting preclinical data from its SIRPaFc immune checkpoint inhibitor...

Apr 10, 2018 07:00 am ET

Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs

TORONTO, April 10, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following update on its TTI-621 and TTI-622 clinical programs. TTI-621 and...

Mar 20, 2018 07:00 am ET

Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma

TORONTO, March 20, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq:TRIL) (TSX:TRIL), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development...

Feb 09, 2018 07:00 am ET

Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

Feb 09, 2018 06:58 am ET

Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter

Jan 17, 2018 07:00 am ET

Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

Jan 17, 2018 06:58 am ET

Trillium Therapeutics Enhances Senior Management Team to Support Further Clinical Development of TTI-621

Dec 11, 2017 08:00 am ET

Trillium Therapeutics Provides Update on its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the American Society of Hematology 59th Annual Meeting, December 9-12, in Atlanta.

Dec 11, 2017 07:58 am ET

Trillium Therapeutics Provides Update on its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

Dec 01, 2017 10:21 pm ET

Trillium Announces Closing of Private Placement

Dec 01, 2017 10:21 pm ET

Trillium Announces Closing of Private Placement

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its non-brokered private placement, previously announced on November 15, 2017, of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share for gross proceeds of U.S.$19,975,000.

Nov 20, 2017 07:00 am ET

Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data for its novel covalent EGFR inhibitor were presented at the Society for Neuro-Oncology 22nd Annual Meeting, November 16-19, in San Francisco.

Nov 20, 2017 06:58 am ET

Trillium Therapeutics' TTI-2341 EGFR Inhibitor Program Featured at the Society for Neuro-Oncology 22nd Annual Meeting

Nov 15, 2017 09:38 am ET

IIROC Trade Resumption - TRIL

TORONTO, Nov. 15, 2017 /CNW/ - Trading resumes in:

Nov 15, 2017 09:35 am ET

IIROC Trading Halt - TRIL

TORONTO, Nov. 15, 2017 /CNW/ - The following issues have been halted by IIROC:

Nov 15, 2017 09:21 am ET

IIROC Trade Resumption - Trillium Therapeutics Inc.

Toronto, Ontario--(Newsfile Corp. - November 15, 2017) - Trading resumes in:

Nov 15, 2017 09:15 am ET

IIROC Trade Halt - Trillium Therapeutics Inc.

Toronto, Ontario--(Newsfile Corp. - November 15, 2017) - The following issues have been halted by IIROC:

Nov 15, 2017 09:15 am ET

Trillium Announces Private Placement

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has entered into subscription agreements for the sale of 1,950,000 common shares and 400,000 Series II non-voting convertible first preferred shares at a price of U.S.$8.50 per share, in a non-brokered private placement for gross proceeds of U.S.$19,975,000.

Nov 15, 2017 09:13 am ET

Trillium Announces Private Placement

Nov 13, 2017 07:00 am ET

Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical and clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented this weekend at the Society for Immunotherapy of Cancer 32nd Annual Meeting in National Harbor, Maryland USA.

Nov 13, 2017 06:58 am ET

Trillium Therapeutics' TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

Nov 10, 2017 07:00 am ET

Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2017.

Nov 10, 2017 06:58 am ET

Trillium Therapeutics Reports Third Quarter 2017 Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the nine months ended September 30, 2017. "Our...

Nov 06, 2017 07:00 am ET

Trillium Therapeutics to Present at Upcoming Scientific Conferences

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming scientific conferences.

Nov 06, 2017 06:58 am ET

Trillium Therapeutics to Present at Upcoming Scientific Conferences

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and...

Oct 16, 2017 07:00 am ET

Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting "Cutaneous Lymphomas - Insights and Therapeutic Progress", October 13-15, in London, England.

Oct 16, 2017 06:58 am ET

Trillium Therapeutics' TTI-621 Program Featured at the EORTC CLTF Cutaneous Lymphoma Conference

Oct 11, 2017 07:00 am ET

Trillium Therapeutics Welcomes Dr. Helen Tayton-Martin to Its Board of Directors

Sep 14, 2017 08:00 am ET

Trillium Therapeutics to Present at Investor and Scientific Conferences in September

NASDAQ: TRIL TSX: TRIL

Sep 14, 2017 08:00 am ET

Trillium Therapeutics to Present at Investor and Scientific Conferences in September

NASDAQ: TRIL TSX: TRIL

Aug 11, 2017 07:00 am ET

Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the six months ended June 30, 2017.

Aug 11, 2017 06:58 am ET

Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the six months ended June...

Jul 05, 2017 06:58 am ET

Trillium Provides Update on Small Molecule Programs

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided an update on its preclinical small molecule programs. Trillium's small...

Jun 28, 2017 03:45 pm ET

Trillium Announces Partial Exercise of Over-Allotment Option

Trillium Therapeutics Inc. (TSX: TRIL)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the underwriters of its recent public offering have exercised their over-allotment option by purchasing an additional 199,674 common shares at a price of US$5.00 per share, for additional gross proceeds to Trillium of US$998,370. Closing of the partial exercise of the over-allotment option was completed today.

Jun 28, 2017 03:43 pm ET

Trillium Announces Partial Exercise of Over-Allotment Option

Jun 07, 2017 07:00 am ET

Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company, today announced that based upon promising early evidence of anti-tumor activity in patients with both myeloid and lymphoid malignancies, it has further expanded its current intravenous dosing trial of TTI-621, an IgG1 SIRPaFc fusion protein targeting CD47.

Jun 07, 2017 06:58 am ET

Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company, today announced that based upon promising early evidence of anti-tumor activity in patients with both myeloid and lymphoid malignancies, it has further...

Jun 01, 2017 04:10 pm ET

Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares were sold at a public offering price of US$5.00 per share and the Series II Non-Voting Convertible First Preferred Shares were sold at a public offering price of US$5.00 per share. The gross proceeds to the Company from this offering are

Jun 01, 2017 04:08 pm ET

Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

May 31, 2017 07:00 am ET

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from June 2-6.

May 31, 2017 06:58 am ET

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

May 26, 2017 04:05 pm ET

Trillium Announces Voting Results from the Annual Meeting of Shareholders

May 26, 2017 04:04 pm ET

Trillium Announces Voting Results from the Annual Meeting of Shareholders

May 26, 2017 09:38 am ET

IIROC Trade Resumption - TRIL

TORONTO, May 26, 2017 /CNW/ - Trading resumes in:

May 26, 2017 09:34 am ET

IIROC Trading Halt - TRIL

TORONTO, May 26, 2017 /CNW/ - The following issues have been halted by IIROC:

May 26, 2017 08:30 am ET

Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of US$5.00 per share and the Series II Non-Voting Convertible First Preferred Shares are being sold at a public offering price of US$5.00 per share. The gross proceeds to the Company from this

May 26, 2017 08:28 am ET

Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares

May 25, 2017 04:01 pm ET

Trillium Announces Proposed Public Offering

Trillium Therapeutics Inc. (TSX: TRIL)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of its common shares and Series II Non-Voting Convertible First Preferred Shares. The Series II Non-Voting Convertible First Preferred Shares are being offered to investors whose purchase of common shares in the offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company's outstanding common shares

May 25, 2017 03:59 pm ET

Trillium Announces Proposed Public Offering

May 12, 2017 07:00 am ET

Trillium Reports First Quarter 2017 Financial and Operating Results

Trillium Therapeutics Inc. (TSX: TRIL)(NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended March 31, 2017.

May 12, 2017 06:58 am ET

Trillium Reports First Quarter 2017 Financial and Operating Results

Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the three months ended...

Apr 03, 2017 07:00 am ET

Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

Trillium Therapeutics Inc. (TSX: TRIL) (NASDAQ: TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following preclinical and clinical updates on its TTI-621 program.

Apr 03, 2017 06:58 am ET

Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

Trillium Therapeutics Inc. (TSX:TRIL) (NASDAQ:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following preclinical and clinical updates on its TTI-621 program....

Mar 29, 2017 07:00 am ET

Trillium Therapeutics to Present at Investor and Scientific Conferences in April

Mar 29, 2017 06:58 am ET

Trillium Therapeutics to Present at Investor and Scientific Conferences in April

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and...

Mar 10, 2017 07:00 am ET

Trillium Reports Annual 2016 Financial and Operating Results

Mar 10, 2017 06:58 am ET

Trillium Reports Annual 2016 Financial and Operating Results

Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today provided a corporate update and reported financial results for the year ended December...

Feb 24, 2017 11:30 am ET

Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today presented new pharmacology data from its ongoing Phase 1 a/b trial of TTI-621, a SIRPaFc fusion protein targeting CD47 in patients with advanced hematologic malignancies. The presentation took place at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.

Feb 24, 2017 11:28 am ET

Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-621

Feb 15, 2017 07:00 am ET

Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will present new data from the Phase 1 trial of its anti-CD47 checkpoint inhibitor TTI-621 at the ASCO-SITC Clinical Immuno-Oncology Symposium on February 24, in Orlando, Florida.

Feb 15, 2017 06:58 am ET

Ad blocking detected

Trillium Therapeutics Inc. (T:TRIL)

Business Focus: N/A